Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been given an average rating of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $107.90.

A number of research analysts recently weighed in on GPCR shares. Guggenheim upped their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Morgan Stanley boosted their price objective on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Stifel Nicolaus upped their target price on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Wall Street Zen upgraded Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, HC Wainwright lifted their price target on shares of Structure Therapeutics from $90.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, March 2nd.

Structure Therapeutics Trading Down 2.1%

GPCR opened at $56.50 on Tuesday. The company has a fifty day moving average price of $74.46 and a two-hundred day moving average price of $48.67. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90. The company has a market cap of $4.00 billion, a P/E ratio of -71.52 and a beta of -1.79.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). On average, research analysts forecast that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. CWM LLC increased its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. HighTower Advisors LLC boosted its stake in Structure Therapeutics by 3.6% during the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after purchasing an additional 320 shares during the last quarter. State of Wyoming increased its holdings in Structure Therapeutics by 29.7% during the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock worth $122,000 after purchasing an additional 403 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Structure Therapeutics by 9.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after purchasing an additional 413 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Structure Therapeutics by 4.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after purchasing an additional 444 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.